Neuronavigation-guided brain surgery - A retrospective case series from Malawi (2022-2025)

神经导航引导脑外科手术——马拉维回顾性病例系列研究(2022-2025)

阅读:1

Abstract

BACKGROUND: Neuronavigation (NN) has become an essential tool in modern neurosurgery, enabling more precise and safer intracranial procedures. While its use is well-documented in high-income settings, there are limited data from Low- and middle-income countries (LMICs), particularly in Sub-Saharan Africa (SSA). This study presents a retrospective case series of NN-guided neurosurgical procedures performed in Malawi, aiming to describe the patient demographics, surgical indications, and interventions over a three-year period. METHODS: We conducted a retrospective review of all patients who underwent NN-guided cranial surgery at Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, between January 2022 and April 2025. Data collected included demographics, diagnosis, intervention type, and outcomes. Outcomes were assessed from discharge status, postoperative complications, and one-month survival. Due to limited follow-up, analysis was restricted to in-hospital and early postoperative periods. RESULTS: 117 patients underwent NN-guided cranial procedures; 52 (44.4 %) were female. The most common procedure was craniotomy for tumor resection (94; 80.3 %). Other procedures included open biopsy (7; 6.0 %), stereotactic biopsy (7; 6.0 %), cerebral abscess drainage (4; 3.4 %), bone tumor excision (2; 1.7 %), intracranial cyst fenestration (1; 0.9 %), endoscopic third ventriculostomy (ETV) (1; 0.9 %), and scalp mass excision (1; 0.9 %). At one month, 57/117 (48.7 %) were alive; 26/117 (22.2 %) died, 3/117 (2.6 %) were discharged palliatively, and 1/117 (0.9 %) had a complication. Overall, 30/117 (25.6 %) experienced a poor outcome, this group includes the 26 deaths, the 3 palliative discharges, and the 1 postoperative complication. CONCLUSION: NN-guided cranial surgery was successfully implemented at a tertiary hospital in Malawi, with tumor resection as the predominant indication. Early outcomes were encouraging, supporting NN's feasibility and clinical value in low-resource settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。